74 à 1

DRUG3 trials

Sponsors

Centre Hospitalier Regional Et Universitaire De Brest, Centre Hospitalier Universitaire De Bordeaux

Conditions

CancerCholangiocarcinomaGastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adultsPancreatic adenocarcinomaThromboembolic event

Phase 2

"Imaging with 68Ga-DOTA-peptides and peptide receptor radionuclide therapy with 177Lu-DOTA-peptides of gastroenteropancreatic neuroendocrine tumors: interest of intra-arterial hepatic infusion in patients with dominant liver metastases" "LUTARTERIAL"

RecruitingCTIS2024-514785-39-00

Centre Hospitalier Universitaire De BordeauxGastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults

Start: 2021-09-24Target: 23Updated: 2024-11-04

"Diagnostic value of 68Ga-FAPI-46 PET/CT in the initial work-up of pancreatic and biliary cancers eligible to a curative treatment" "FAPDIG"

Not yet recruitingCTIS2024-517270-23-00

Centre Hospitalier Universitaire De BordeauxCholangiocarcinoma, Pancreatic adenocarcinoma

Target: 120Updated: 2025-07-30

Phase 3

Screening for occult malignancy using 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) in patients with unprovoked venous thromboembolism

Active, not recruitingCTIS2024-514703-34-00

Centre Hospitalier Regional Et Universitaire De BrestCancer, Thromboembolic event

Start: 2020-09-08Target: 638Updated: 2024-06-18